

# Brian P Hobbs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8229341/publications.pdf>

Version: 2024-02-01

65  
papers

2,610  
citations

257450  
24  
h-index

214800  
47  
g-index

66  
all docs

66  
docs citations

66  
times ranked

3138  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Use of historical control data for assessing treatment effects in clinical trials. <i>Pharmaceutical Statistics</i> , 2014, 13, 41-54.   | 1.3  | 340       |
| 2  | Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , 2021, 9, 467-475.   | 10.7 | 277       |
| 3  | Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials. <i>Biometrics</i> , 2011, 67, 1047-1056.   | 1.4  | 250       |
| 4  | Time to initial cancer treatment in the United States and association with survival over time: An observational study. <i>PLoS ONE</i> , 2019, 14, e0213209.   | 2.5  | 179       |
| 5  | Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.                                      | 1.6  | 158       |
| 6  | Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 154-160. | 0.6  | 109       |
| 7  | Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 1922.   | 3.3  | 108       |
| 8  | Adaptive adjustment of the randomization ratio using historical control data. <i>Clinical Trials</i> , 2013, 10, 430-440.  | 1.6  | 86        |
| 9  | Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2019, 20, 1386-1394.                  | 10.7 | 69        |
| 10 | Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. <i>International Journal of Particle Therapy</i> , 2017, 4, 23-32.  | 1.8  | 69        |
| 11 | Bayesian basket trial design with exchangeability monitoring. <i>Statistics in Medicine</i> , 2018, 37, 3557-3572.   | 1.6  | 67        |
| 12 | Controlled multi-arm platform design using predictive probability. <i>Statistical Methods in Medical Research</i> , 2018, 27, 65-78.   | 1.5  | 65        |
| 13 | Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. , 2021, 9, e001719.   |      | 62        |
| 14 | Histology-agnostic drug development “considering issues beyond the tissue. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 555-568.  | 27.6 | 60        |
| 15 | Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. <i>Intensive Care Medicine</i> , 2017, 43, 785-794.   | 8.2  | 55        |
| 16 | Bayesian hierarchical modeling based on multisource exchangeability. <i>Biostatistics</i> , 2018, 19, 169-184.   | 1.5  | 49        |
| 17 | Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.  | 6.3  | 49        |
| 18 | Increased incidence of venous thromboembolism with cancer immunotherapy. <i>Med</i> , 2021, 2, 423-434.e3.   | 4.4  | 46        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. International Journal of Radiation Oncology Biology Physics, 2017, 98, 811-819. | 0.8 | 41        |
| 20 | A Multi-Source Adaptive Platform Design for Testing Sequential Combinatorial Therapeutic Strategies. Biometrics, 2018, 74, 1082-1094.  | 1.4 | 38        |
| 21 | Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. Journal of Thoracic Oncology, 2020, 15, 101-109.   | 1.1 | 38        |
| 22 | Moving Beyond 3+3: The Future of Clinical Trial Design. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e133-e144.                      | 3.8 | 33        |
| 23 | Bayesian Group Sequential Clinical Trial Design Using Total Toxicity Burden and Progression-Free Survival. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 273-297.           | 1.0 | 32        |
| 24 | Phase II study of Dovitinib in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 144, 359-368.  | 2.9 | 29        |
| 25 | Metastases to the Liver from Neuroendocrine Tumors: Effect of Duration of Scan Acquisition on CT Perfusion Values. Radiology, 2013, 269, 758-767.  | 7.3 | 27        |
| 26 | Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis. Scientific Reports, 2019, 9, 18126.  | 3.3 | 26        |
| 27 | Spatial Bayesian modeling of GLCM with application to malignant lesion characterization. Journal of Applied Statistics, 2019, 46, 230-246.   | 1.3 | 23        |
| 28 | A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. , 2019, 7, 127.  |     | 23        |
| 29 | Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 4985-4994.  | 1.5 | 17        |
| 30 | The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers, 2022, 14, 1304.                                 | 3.7 | 17        |
| 31 | Current status and application of proton therapy for esophageal cancer. Radiotherapy and Oncology, 2021, 164, 27-36.   | 0.6 | 13        |
| 32 | Bayesian Predictive Modeling for Genomic Based Personalized Treatment Selection. Biometrics, 2016, 72, 575-583.  | 1.4 | 12        |
| 33 | Web-based statistical tools for the analysis and design of clinical trials that incorporate historical controls. Computational Statistics and Data Analysis, 2018, 127, 50-68.                                 | 1.2 | 12        |
| 34 | Combining nonexchangeable functional or survival data sources in oncology using generalized mixture commensurate priors. Annals of Applied Statistics, 2015, 9, 1549-1570.                                     | 1.1 | 11        |
| 35 | Basket Designs: Statistical Considerations for Oncology Trials. JCO Precision Oncology, 2019, 3, 1-9.  | 3.0 | 11        |
| 36 | Basket Trials: Review of Current Practice and Innovations for Future Trials. Journal of Clinical Oncology, 2022, 40, 3520-3528.  | 1.6 | 10        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 369-372.                                  | 1.4 | 9         |
| 38 | The Diminishing Impact of Margin Definitions and Width on Local Recurrence Rates following Breast-Conserving Therapy for Early-Stage Invasive Cancer: A Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4628-4636. | 1.5 | 9         |
| 39 | Statistical design considerations for trials that study multiple indications. <i>Statistical Methods in Medical Research</i> , 2021, 30, 785-798.  | 1.5 | 9         |
| 40 | Predictive classification of correlated targets with application to detection of metastatic cancer using functional CT imaging. <i>Biometrics</i> , 2015, 71, 792-802.   | 1.4 | 7         |
| 41 | Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants. <i>Biometrical Journal</i> , 2019, 61, 902-917.   | 1.0 | 7         |
| 42 | Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1044-1053.                         | 2.1 | 7         |
| 43 | Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. <i>Statistical Methods in Medical Research</i> , 2018, 27, 2093-2113.   | 1.5 | 4         |
| 44 | Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis. <i>Clinical Breast Cancer</i> , 2020, 20, e625-e650.                       | 2.4 | 4         |
| 45 | A survival mediation model with Bayesian model averaging. <i>Statistical Methods in Medical Research</i> , 2021, 30, 2413-2427.  | 1.5 | 4         |
| 46 | Bayesian basket trial design with false-discovery rate control. <i>Clinical Trials</i> , 2022, , 174077452110736.  | 1.6 | 4         |
| 47 | A functional model for classifying metastatic lesions integrating scans and biomarkers. <i>Statistical Methods in Medical Research</i> , 2020, 29, 137-150.  | 1.5 | 3         |
| 48 | Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. <i>Statistics in Medicine</i> , 2022, 41, 751-768.  | 1.6 | 3         |
| 49 | A Bayesian nonparametric model for textural pattern heterogeneity. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2021, 70, 459-480.   | 1.0 | 2         |
| 50 | The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. <i>Blood</i> , 2019, 134, 16-16.   | 1.4 | 2         |
| 51 | Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. <i>Blood</i> , 2019, 134, 381-381.   | 1.4 | 2         |
| 52 | Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. <i>JCO Precision Oncology</i> , 2022, 6, e2100390.   | 3.0 | 2         |
| 53 | Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 1001-1005.  | 0.8 | 1         |
| 54 | Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , 2018, 132, 4806-4806.   | 1.4 | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS. Blood, 2019, 134, 1716-1716.   | 1.4 | 1         |
| 56 | Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.. Journal of Clinical Oncology, 2019, 37, 1032-1032. | 1.6 | 1         |
| 57 | A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. Blood, 2019, 134, 2595-2595.                 | 1.4 | 1         |
| 58 | Calibrated dynamic borrowing using capping priors. Journal of Biopharmaceutical Statistics, 2021, 31, 852-867.  | 0.8 | 1         |
| 59 | Estimating mean local posterior predictive benefit for biomarker-guided treatment strategies. Statistical Methods in Medical Research, 2019, 28, 2820-2833.   | 1.5 | 0         |
| 60 | Comparing phase 3 "go/no-go" decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2).. Journal of Clinical Oncology, 2021, 39, e13564-e13564.  | 1.6 | 0         |
| 61 | Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. Blood, 2018, 132, 1527-1527.  | 1.4 | 0         |
| 62 | Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies. Blood, 2019, 134, 3433-3433.  | 1.4 | 0         |
| 63 | Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients. Blood, 2019, 134, 3836-3836.   | 1.4 | 0         |
| 64 | A group sequential randomized trial design utilizing supplemental trial data. Statistics in Medicine, 2021, , .   | 1.6 | 0         |
| 65 | An 11-gene expression signature related to tumorigenesis and immunosuppression in primary cutaneous melanoma predicts sentinel lymph node metastatic status.. Journal of Clinical Oncology, 2022, 40, e21579-e21579.    | 1.6 | 0         |